OSAKA, Japan - Shionogi & Co., Ltd. (Head Office: Osaka, Japan; President and CEO: Isao Teshirogi, Ph.D.; hereafter 'Shionogi') announced that Shionogi will implement the following corporate reorganization and personnel reassignment as of July 1, 2021.
1. Corporate Reorganization
(1) New establishment of the DX Promotion Division
The DX Promotion Division will be newly established to assume the role of creating healthcare solutions using digital technology, making use of data to support the realization of the solutions, and building IT and security infrastructure. The Digital Intelligence Department of the Corporate Strategy Division will be incorporated into the DX Promotion Division. In addition, the related functions of the Corporate Planning Department of the Corporate Strategy Division and the Data Science Office of the Integrated Disease Care Division will be reorganized into the IT & Digital Solution Department and the Data Science Department under the DX Promotion Division.
(2) Reorganization of the Pharmaceutical Research Division
The Biomarker R&D Department, which has been an independent organization, will be incorporated into the Pharmaceutical Research Division to further strengthen the collaboration between research on disease prevention and treatment and research on diagnosis and biomarkers.
(3) Reorganization of the Pharmaceutical Commercial Division
Under the reorganization of the functions of the Sales Planning Department, the Sales Planning Office, which is responsible for improving, reforming, and supervising the operations of the entire Pharmaceutical Commercial Division, and the Sales Promotion Office, which is responsible for planning and promoting sales activities, including promoting disease strategies through activities for core hospitals centered on university hospitals, will be newly established.
(4) Reorganization of the Integrated Disease Care Division
The Disease Care Strategy Department will be incorporated and integrated into the New Product Planning Department to make the commercial strategy globally consistent from the research phase to the post-marketing phase, thereby further enhancing the comprehensive strategy planning function related to healthcare services. The Disease Care Strategy Office will be established under the New Product Planning Department to take on the planning function for each disease area in Japan.
(5) Reorganization of the Global Business Division
The Global Supply Chain Strategy Department of the Corporate Strategy Division will be under the Global Business Division to strengthen the business collaboration between global business and procurement and supply strategy planning functions.
(6) Reorganization of the Corporate Strategy Division
The Business Development Department of the Global Business Division will be incorporated into the Corporate Strategy Division to more strategically promote collaborative creation with various partners, which is the core activity in our Medium-Term Business Plan 'Shionogi Transformation Strategy 2030 (STS2030)'.
(7) Reorganization of the Administration Division
The Sustainability Management Office of the Corporate Planning Department, Corporate Strategy Division, will be incorporated as the Sustainability Management Department under the Administration Division to promote fair corporate activities and further enhance governance and compliance functions while deepening collaboration with organizations in each Division. Meanwhile, to make the independence of the internal audit function clearer, the Internal Control Department will be directly under the President, independent of all Divisions.
Contact:
Tel: +81-6-6202-2161
SHIONOGI & CO., LTD. 
